Endoscopic Radiofrequency Ablation or Cryoablation for Barrett’s Esophagus

Policy # 00261
Original Effective Date: 06/16/2010
Current Effective Date: 01/08/2020

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Oncologic Applications of Photodynamic Therapy, Including Barrett’s Esophagus is addressed in medical policy 00234.

Note: Confocal Laser Endomicroscopy is addressed separately in medical policy 00416.

When Services Are Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:
- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider radiofrequency ablation (RFA) for treatment of Barrett’s esophagus (BE) with either high-grade dysplasia (HGD) or low-grade dysplasia (LGD) to be eligible for coverage.**

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers radiofrequency ablation (RFA) for treatment of Barrett’s esophagus (BE) in the absence of dysplasia to be investigational.*

Based on review of available data, the Company considers cryoablation for Barrett’s esophagus (BE), with or without dysplasia to be investigational.*
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett’s Esophagus

Policy # 00261
Original Effective Date: 06/16/2010
Current Effective Date: 01/08/2020

**Background/Overview**

**Diagnosis**

Radiofrequency ablation for Barrett esophagus with high-grade dysplasia may be used in combination with endoscopic mucosal resection of nodular or visible lesions. The diagnosis of high-grade dysplasia should be confirmed by 2 pathologists before initiating radiofrequency ablation.

There is considerable interobserver variability in the diagnosis of low-grade dysplasia (LGD), and the potential exists for overdiagnosis of LGD by nonexpert pathologists (overdiagnosis is due primarily to the difficulty in distinguishing inflammatory changes from LGD). There is evidence in the literature that expert gastrointestinal pathologists will downgrade a substantial portion of biopsies that are initially read as LGD by nonexperts (Curvers et al [2010]; Kerkhof et al [2007]). As a result, it is ideal that 2 experts in gastrointestinal pathology agree on the diagnosis to confirm LGD; this may result in greater than 75% of initial diagnoses of LGD being downgraded to nondysplasia (Curvers et al [2010]). A review by a single expert gastrointestinal pathologist will also result in a large number of LGD diagnoses being downgraded, although probably not as many as achieved using 2 expert pathologists (Kerkhof et al, 2007).

**Management of Barrett Esophagus**

The management of BE includes the treatment of gastroesophageal reflux disease and surveillance endoscopy to detect progression to high-grade dysplasia or adenocarcinoma. The finding of high-grade dysplasia or early-stage adenocarcinoma warrants mucosal ablation or resection (either endoscopic mucosal resection [EMR] or esophagectomy).

EMR, either focal or circumferential, provide a histologic specimen for examination and staging (unlike ablative techniques). One 2007 study provided long-term results for EMR in 100 consecutive patients with early Barrett-associated adenocarcinoma (limited to the mucosa). The 5-year overall survival was 98% and, after a mean of 36.7 months, metachronous lesions were observed in 11% of patients. In a review by Pech and Ell (2009), the authors stated that circumferential EMR of the entire segment of BE leads to a stricture rate of 50%, and recurrences occur at a rate of up to 11%.

**Ablative Techniques**

Available mucosal ablation techniques that include several thermal (multipolar electrocoagulation [MPEC], argon plasma coagulation [APC], heater probe, Nd:YAG laser, KTP-YAG laser, diode
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett’s Esophagus

Policy # 00261
Original Effective Date: 06/16/2010
Current Effective Date: 01/08/2020

laser, argon laser, cryoablation) or nonthermal (5-aminolevulinic acid, photodynamic therapy) techniques. In a randomized phase 3 trial reported by Overholt et al (2005), photodynamic therapy was shown to decrease significantly the risk of adenocarcinoma in BE. (Photodynamic therapy for BE is discussed in medical policy 00234.)

The CryoSpray Ablation system uses a low-pressure spray for applying liquid nitrogen through an upper endoscope. Cryotherapy allows for the treatment of uneven surfaces; however, a disadvantage of the treatment is the uneven application inherent in spraying the cryogen.

The HALO system uses radiofrequency energy and consists of two components: an energy generator and an ablation catheter. The generator provides rapid (ie, <1 second) delivery of a predetermined amount of radiofrequency energy to the catheter. The HALO90 or the HALO360 is inserted into the esophagus with an endoscope, using standard endoscopic techniques. The HALO90 catheter is plate-based and used for focal ablation of areas of BE up to 3 cm. HALO360 uses a balloon catheter that is sized to fit the individual’s esophagus and is inflated to allow for circumferential ablation.

Radiofrequency ablation affects only the most superficial layer of the esophagus (ie, the mucosa), leaving the underlying tissues unharmed. Measures of efficacy for the procedure are the eradication of intestinal metaplasia and the postablation regrowth of the normal squamous epithelium. (Note: The eradication of intestinal metaplasia does not leave behind microscopic foci). Reports of the efficacy of the HALO system in ablating BE have been as high as 70% (comparable with alternative methods of ablation [eg, APC, MPEC]), and even higher in some reports. The incidence of leaving behind microscopic foci of intestinal metaplasia has been reported to be between 20% and 44% with APC and 7% with MPEC; studies using the HALO system have reported 0%. Another potential advantage of the HALO system is that it is an automated process that eliminates operator-dependent error, which may be seen with APC or MPEC.

The risk of treating high-grade dysplasia or mucosal cancer solely with ablative techniques is undertreatment for approximately 10% of patients with undetected submucosal cancer, in whom esophagectomy would have been required.
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett’s Esophagus

Policy # 00261
Original Effective Date: 06/16/2010
Current Effective Date: 01/08/2020

**FDA or Other Governmental Regulatory Approval**

**U.S. Food and Drug Administration (FDA)**

In 2005, the HALO360 (now Barrx™ 360 RFA Balloon Catheter; Barrx Medical; acquired by Covidien in 2012) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process and, in 2006, the HALO90 (now Barrx™ 90 RFA Focal Catheter) received clearance. The FDA-labeled indications are for use in coagulation of bleeding and nonbleeding sites in the gastrointestinal tract and include the treatment of BE. FDA product code: GEI.

In 2007, the CryoSpray Ablation™ System (formerly the SprayGenix Cryo Ablation system; CSA Medical) was cleared for marketing by the FDA through the 510(k) process for use as a “cryosurgical tool for destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications.” FDA product code: GEH.

In 2002, the Polar Wand® device (Chek-Med Systems), a cryosurgical device that uses compressed carbon dioxide, was cleared for marketing by the FDA through the 510(k) process. Indications for use are “ablation of unwanted tissue in the fields of dermatology, gynecology, general surgery, urology, and gastroenterology.”

**Rationale/Source**

In Barrett esophagus (BE), the normal squamous epithelium is replaced by specialized columnar-type epithelium, known as intestinal metaplasia. Intestinal metaplasia is a precursor to adenocarcinoma and may be treated with mucosal ablation techniques such as radiofrequency ablation (RFA) or cryoablation.

For individuals who have BE with high-grade dysplasia (HGD) who receive endoscopic RFA, the evidence includes a randomized controlled trial (RCT) comparing radical endoscopic resection with focal endoscopic resection followed by RFA, an RCT comparing RFA with surveillance alone, and a number of observational studies, some of which compared RFA with other endoscopic treatment modalities. The relevant outcomes are overall survival (OS), change in disease status, morbid events, and treatment-related morbidity and mortality. The available evidence has shown that using RFA to treat BE with HGD is at least as effective in eradicating HGD as other ablative techniques, with a lower progression rate to cancer, and may be considered an alternative to esophagectomy. Evidence
from at least one RCT has demonstrated higher rates of eradication than surveillance alone. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have BE with low-grade dysplasia (LGD) who receive endoscopic RFA, the evidence includes at least two RCTs comparing RFA with surveillance alone, a number of observational studies, and systematic reviews of these studies. The relevant outcomes are OS, change in disease status, morbid events, and treatment-related morbidity and mortality. For patients with confirmed LGD, evidence from an RCT has suggested that RFA reduces progression to HGD and adenocarcinoma. Challenges exist in differentiating between nondysplastic BE and BE with LGD; making the correct diagnosis has important implications for LGD treatment decisions. One of the available RCTs required that LGD be confirmed by an expert panel, which supports the use of having a gastrointestinal pathologist confirm LGD before treatment of BE with LGD can begin. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Clinical input was obtained in 2012, and it generally supported the use of RFA for BE with LGD. Input indicated that it is possible to define a population with a higher risk of progression by having the initial diagnosis of LGD reconfirmed by an expert in gastrointestinal pathology.

For individuals who have BE without dysplasia who receive endoscopic RFA, the evidence includes single-arm studies reporting outcomes after RFA. The relevant outcomes are OS, change in disease status, morbid events, and treatment-related morbidity and mortality. The available studies have suggested that nondysplastic metaplasia can be eradicated by RFA. However, the risk-benefit ratio and the net effect of RFA on health outcomes are unknown. The evidence is insufficient to determine the effects of technology on net health outcomes.

For individuals who have BE with or without dysplasia who receive endoscopic cryoablation, the evidence includes noncomparative studies reporting outcomes after cryoablation. The relevant outcomes include OS, change in disease status, morbid events, and treatment-related morbidity and mortality. These studies have generally demonstrated high rates of eradication of dysplasia. However, the available evidence does not compare cryoablation with surgical care or RFA. The evidence is insufficient to determine the effects of technology on net health outcomes.
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett’s Esophagus

Policy # 00261
Original Effective Date: 06/16/2010
Current Effective Date: 01/08/2020

Supplemental Information
Clinical Input From Physician Specialty Societies and Academic Medical Centers
While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2012 Input
In response to requests, input was received from reviewers at 6 academic medical centers and from 1 subspecialty medical society while this policy was under review in 2012. Input related to the treatment of low-grade dysplasia (LGD) was mixed, with two reviewers stating that radiofrequency ablation (RFA) for LGD should be investigational, three indicating that it should be medically necessary, and two indicating that it was a split decision. There was a general consensus among reviewers that there are subsets of patients with LGD who have a higher risk and should, therefore, be treated. Reviewers mentioned that factors useful in defining higher risk populations for whom treatment is warranted are the confirmation of LGD diagnosis by multiple pathologists and/or the application of clinical high-risk factors such as lesion length.

2009 Input
In response to requests, input was received from 3 academic medical centers and 1 subspecialty medical society (with 12 reviewers) while this policy was under review in 2009. All reviewers agreed that RFA (cryoablation was not included in the request) should be considered medically necessary for the treatment of Barrett esophagus (BE) with high-grade dysplasia. Reviewers were split for the use of RFA for LGD, with nine considered it medically necessary and four considering it investigational.

Practice Guidelines and Position Statements
American College of Gastroenterology
The American College of Gastroenterology (2016) issued guidelines on the diagnosis and management of BE, which made statements about endoscopic therapies in general, as outlined in Table 1.
## Table 1. Guidelines on the Diagnosis and Management of BE

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>SOR</th>
<th>LOE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with nodularity in the BE segment should undergo endoscopic mucosal resection of the nodular lesion(s) as the initial diagnostic and therapeutic maneuver…. Histologic assessment of the EMR specimen should guide further therapy. In subjects with EMR specimens demonstrating HGD or IMC, endoscopic ablative therapy of the remaining BE should be performed.</td>
<td>Strong</td>
<td>High</td>
</tr>
<tr>
<td>In patients with EMR specimens demonstrating neoplasia at a deep margin, residual neoplasia should be assumed, and surgical, systemic, or additional endoscopic therapies should be considered</td>
<td>Strong</td>
<td>Low</td>
</tr>
<tr>
<td>Endoscopic ablative therapies should not be routinely applied to patients with nondysplastic BE because of their low risk of progression to EAC. Endoscopic eradication therapy is the procedure of choice for patients with confirmed LGD, and confirmed HGD, as noted above</td>
<td>Strong</td>
<td>Very low</td>
</tr>
<tr>
<td>In patients with T1a EAC, endoscopic therapy is the preferred therapeutic approach, being both effective and well-tolerated</td>
<td>Strong</td>
<td>Moderate</td>
</tr>
<tr>
<td>In patients with T1b EAC, consultation with multidisciplinary surgical oncology team should occur before embarking on endoscopic therapy. In such patients, endoscopic therapy may be an alternative strategy to esophagectomy, especially in those</td>
<td>Strong</td>
<td>Low</td>
</tr>
</tbody>
</table>
with superficial (sm1) disease with a well-differentiated neoplasm lacking lymphovascular invasion, as well as those who are poor surgical candidates

Routine staging of patients with nodular BE with EUS or other imaging modalities before EMR has no demonstrated benefit. Given the possibility of over- and understaging, findings of these modalities should not preclude the performance of EMR to stage-early neoplasia

In patients with known T1b disease, EUS may have a role in assessing and sampling regional lymph nodes, given the increased prevalence of lymph node involvement in these patients compared with less advanced disease

In patients with dysplastic BE who are to undergo endoscopic ablative therapy for nonnodular disease, radiofrequency ablation is currently the preferred endoscopic ablative therapy

BE: Barrett esophagus; EAC: esophageal adenocarcinoma; EMR: endoscopic mucosal resection; EUS: endoscopic ultrasound; HGD: high-grade dysplasia; IMC: intramucosal carcinoma; LGD: low-grade dysplasia; LOE: level of evidence; SOR: strength of recommendation.

American Society for Gastrointestinal Endoscopy
The American Society for Gastrointestinal Endoscopy (2018) issued guidelines on the role of endoscopy in BE-associated dysplasia and intramucosal cancer. These guidelines made the following recommendations on endoscopic eradication therapy, consisting of endoscopic mucosal resection of visible lesions and ablative techniques that include RFA and cryotherapy (see Table 2).
### Table 2. Guidelines on Use of Endoscopy for BE and IMC

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>SOR</th>
<th>QOE&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>In BE patients with LGD and HGD being considered for EET, we suggest confirmation of diagnosis by at least 1 expert GI pathologist or panel of pathologists compared with review by a single pathologist.</td>
<td>Conditional</td>
<td>Low</td>
</tr>
<tr>
<td>In BE patients with LGD, we suggest EET compared with surveillance; however, patients who place a high value on avoiding adverse events related to EET may choose surveillance as the preferred option.</td>
<td>Conditional</td>
<td>Moderate</td>
</tr>
<tr>
<td>In BE patients with confirmed HGD, we recommend EET compared with surveillance</td>
<td>Strong</td>
<td>Moderate</td>
</tr>
<tr>
<td>In BE patients with HGD/IMC, we recommend against surgery compared with EET</td>
<td>Strong</td>
<td>Very low quality</td>
</tr>
<tr>
<td>In BE patients referred for EET, we recommend endoscopic resection of all visible lesions compared with no endoscopic resection of visible lesions.</td>
<td>Strong</td>
<td>Moderate</td>
</tr>
<tr>
<td>In BE patients with visible lesions who undergo endoscopic resection, we suggest ablation of the remaining Barrett’s segment compared with no ablation.</td>
<td>Conditional</td>
<td>Low</td>
</tr>
</tbody>
</table>

<sup>a</sup> QOE = Quality of Evidence
In BE patients with dysplasia and IMC referred for EET, we recommend against routine complete endoscopic resection of entire Barrett’s segment compared with endoscopic resection of visible lesion followed by ablation of remaining Barrett’s segment.

In BE patients with dysplasia and IMC who have achieved CE-IM after EET, we suggest surveillance endoscopy versus no surveillance.

BE: Barrett esophagus; CE-IM: complete eradication of intestinal metaplasia; EET: endoscopic eradication therapy; HGD: high-grade dysplasia; LGD: low-grade dysplasia; IMC: intramucosal cancer; QOE: quality of evidence; SOR: strength of recommendation.

Quality assessed using GRADE system.

American Gastroenterological Association
The American Gastroenterological Association (2015) published consensus recommendations on the management of BE, dysplasia, and esophageal adenocarcinoma (see Table 3)

Table 3. Recommendations on Management of BE, Dysplasia, and Esophageal Adenocarcinoma

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>Agreement</th>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>Statements with ≥80% consensus agreement but generally low-quality evidence relevant to RFA for BE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
In patients with BE undergoing endoscopic therapy, endoscopic resection of more than two-thirds of the circumference is not generally recommended due to the risk of stricture.

| Percentage | 83 | 13 | 70 | 17 |

RFA is an acceptable treatment option for BE patients with flat mucosa containing HGD without any visible lesions confirmed by high-resolution, high-definition endoscopy.

| Percentage | 87 | 35 | 52 | 13 |

Statements with consensus agreement <80% relevant to RFA for BE
In patients with BE, all cases of possible dysplasia (indefinite, low grade, high grade) should be reviewed by at least 2 additional pathologists with specific expertise in Barrett’s pathology.

| Value | 60.8 | 8.7 | 26.1 | 4.3 |

Values are percent.
BE: Barrett esophagus; HGD: high-grade dysplasia; RFA: radiofrequency ablation.

Society of American Gastrointestinal and Endoscopic Surgeons
The Society of American Gastrointestinal and Endoscopic Surgeons (2010) published guidelines on the surgical treatment of gastroesophageal reflux disease, which included recommendations for the treatment of BE (see Table 4).

Table 4. Guidelines on Surgical Treatment of Gastroesophageal Reflux Disease

<table>
<thead>
<tr>
<th>Recommendation</th>
<th>GOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>HGIN and IMC can be effectively treated with endoscopic therapy including PDT, EMR, and RFA, alone or in combination.</td>
<td>B</td>
</tr>
<tr>
<td>Antireflux surgery may be performed in a patient with non-neoplastic IM, IND, or LGIN, with or without endoscopic therapy to eradicate Barrett’s tissue. Specifically, RFA has been shown to be safe, clinically effective, and cost-</td>
<td>B</td>
</tr>
</tbody>
</table>
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett’s Esophagus

Policy # 00261
Original Effective Date: 06/16/2010
Current Effective Date: 01/08/2020

Effective in these disease states and may be performed in eligible patients before, during, or after antireflux surgery.

EMR: endoscopic mucosal resection; GOR: grade of recommendation; HGD: high-grade dysplasia; IM: intestinal metaplasia; IMC: intramucosal carcinoma; IND: indeterminate dysplasia; LGD: low-grade dysplasia; PDT: photodynamic therapy; RFA: radiofrequency ablation.

National Comprehensive Cancer Network
National Comprehensive Cancer Network Guidelines (v.2.2019) Esophageal and Esophagogastric Cancers make recommendations about BE and early-stage esophageal adenocarcinomas. For primary treatment; “The goal of endoscopic therapy, [by endoscopic mucosal resection (EMR), endoscopic submucosal dissection (ESD), and/or ablation] is the complete removal or eradication of early-stage disease (pTis, pT1a, and selected superficial pT1b without LVI) and pre-neoplastic tissue (Barrett’s esophagus)."

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently ongoing and unpublished trials that might influence this review are listed in Table 5.
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett’s Esophagus

Policy #  00261
Original Effective Date:  06/16/2010
Current Effective Date:  01/08/2020

Table 5. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01961778</td>
<td>Prospective Randomized Trial Comparing Radiofrequency Ablation (Barrx™) and Cryotherapy (truFreeze™) for the Treatment of Barrett’s Esophagus With High-Grade Dysplasia and/or Early Adenocarcinoma</td>
<td>50</td>
<td>Feb 2020</td>
</tr>
<tr>
<td>Unpublished</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

References
8. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Radiofrequency ablation of nondysplastic or low-grade dysplastic Barrettâ€™s esophagus. TEC Assessments. 2010;Volume 25:Tab 5.

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett’s Esophagus

Policy # 00261
Original Effective Date: 06/16/2010
Current Effective Date: 01/08/2020

Endoscopic Radiofrequency Ablation or Cryoablation for Barrett’s Esophagus

Policy # 00261
Original Effective Date: 06/16/2010
Current Effective Date: 01/08/2020


Endoscopic Radiofrequency Ablation or Cryoablation for Barrett’s Esophagus

Policy # 00261
Original Effective Date: 06/16/2010
Current Effective Date: 01/08/2020


**Policy History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/16/2010</td>
<td>Medical Policy Committee approval</td>
</tr>
<tr>
<td>06/16/2010</td>
<td>Medical Policy Implementation Committee approval. New policy.</td>
</tr>
<tr>
<td>05/05/2011</td>
<td>Medical Policy Committee approval</td>
</tr>
<tr>
<td>05/18/2011</td>
<td>Medical Policy Implementation Committee approval. No change to coverage.</td>
</tr>
<tr>
<td>04/12/2012</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>04/25/2012</td>
<td>Medical Policy Implementation Committee approval. Radiofrequency ablation for</td>
</tr>
<tr>
<td></td>
<td>treatment of Barrett’s esophagus with low-grade dysplasia was changed from</td>
</tr>
<tr>
<td></td>
<td>investigational to eligible for coverage when the initial diagnosis of low-grade</td>
</tr>
<tr>
<td></td>
<td>dysplasia is confirmed by a second pathologist who is an expert in GI pathology.</td>
</tr>
<tr>
<td></td>
<td>Added that treatment of Barrett’s esophagus with low-grade dysplasia in any other</td>
</tr>
<tr>
<td></td>
<td>situation is investigational.</td>
</tr>
<tr>
<td>03/04/2013</td>
<td>Coding revised</td>
</tr>
<tr>
<td>04/04/2013</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>04/24/2013</td>
<td>Medical Policy Implementation Committee approval. No change to coverage.</td>
</tr>
<tr>
<td>06/25/2013</td>
<td>Medical Policy Implementation Committee approval. Retired medical policy.</td>
</tr>
<tr>
<td>01/09/2014</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>01/15/2014</td>
<td>Medical Policy Implementation Committee approval. “Based on review of available</td>
</tr>
<tr>
<td></td>
<td>data, the Company considers radiofrequency ablation for treatment of Barrett’s</td>
</tr>
<tr>
<td></td>
<td>esophagus in the absence of dysplasia” was changed from investigational to not</td>
</tr>
<tr>
<td></td>
<td>medically necessary. Dropped the requirement of a second pathologist from</td>
</tr>
<tr>
<td></td>
<td>coverage section. Brought back from retired status.</td>
</tr>
<tr>
<td>01/08/2015</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>01/21/2015</td>
<td>Medical Policy Implementation Committee approval. Coverage eligibility unchanged.</td>
</tr>
<tr>
<td>08/03/2015</td>
<td>Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section</td>
</tr>
<tr>
<td></td>
<td>removed.</td>
</tr>
<tr>
<td>01/07/2016</td>
<td>Medical Policy Committee review</td>
</tr>
</tbody>
</table>

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett’s Esophagus

Policy # 00261
Original Effective Date: 06/16/2010
Current Effective Date: 01/08/2020

01/22/2016 Medical Policy Implementation Committee approval. RFA for treatment of BE in the absence of dysplasia is considered investigational.
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
01/05/2017 Medical Policy Committee review
01/18/2017 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/04/2018 Medical Policy Committee review
01/17/2018 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/10/2019 Medical Policy Committee review
01/03/2020 Medical Policy Committee review
01/08/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/15/2020 Coding update

Next Scheduled Review Date: 01/2021

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)⁷, copyright 2019 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not

©2020 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett’s Esophagus

Policy # 00261
Original Effective Date: 06/16/2010
Current Effective Date: 01/08/2020

contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>43229, 43270</td>
</tr>
<tr>
<td>HCPCS</td>
<td>No codes</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>D13.0, K22.70, K22.710, K22.711, K22.719</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.
Endoscopic Radiofrequency Ablation or Cryoablation for Barrett’s Esophagus

Policy # 00261
Original Effective Date: 06/16/2010
Current Effective Date: 01/08/2020

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.